We demonstrated that PKD2 and PKD3 played a critical role in the regulation of tumor angiogenesis and defined a novel model in which PKD2 and PKD3 activate Erk1/2 and NF-κB in prostate cancer cells through promoting SCF, CCL5, and CCL11 expression, which further promote MCs recruitment and expression of angiogenic factors consequently, leading to tumor angiogenesis (Fig. 6e). The gene discussed is MAPK3; the disease is prostate carcinoma.